Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus

Journal of Clinical Oncology

Volumn 29, Issue 9, 2011, Pages

  Larkin, James M G ^a   Fisher, Rosalie A ^a   Pickering, Lisa M ^a   Sohaib, S Aslam ^a   Ghosn, Marwan ^b   Christmas, Tim ^a   Cordiner, Ruth L M ^a   Gore, Martin E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; EVEROLIMUS; LAMIVUDINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; CANCER RECURRENCE; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SUBSTITUTION; GASTROINTESTINAL TOXICITY; HEPATITIS B; HUMAN; INOPERABLE CANCER; KIDNEY CARCINOMA; LETTER; MALE; PRIORITY JOURNAL; SIDE EFFECT; VIRUS REACTIVATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; SIROLIMUS; TREATMENT OUTCOME;

EID: 79952751962     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.4375     Document Type: Letter

References (17)

1. Reuter VE: The pathology of renal epithelial neoplasms. Semin Oncol 33:534-543, 2006
2. Klatte T, Han K, Said JW, et al: Pathobiology and prognosis of chromophobe renal cell carcinoma. Urol Oncol 26:604-609, 2008
3. Motzer RJ, Bacik J, Mariani T, et al: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20:2376-2381, 2002 (Pubitemid 34441667)
4. Cindolo L, De la Taille A, Schips L, et al: Chromophobe renal cell carcinoma: Comprehensive analysis of 104 cases from multicenter European database. Urology 65:681-686, 2005 (Pubitemid 40522999)
5. Beck SD, Patel MI, Snyder ME, et al: Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 11:71-77, 2004
6. Jacobsen J, Grankvist K, Rasmuson T, et al: Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 93:297-302, 2004 (Pubitemid 38253573)
7. Yamazaki K, Sakamoto M, Ohta T, et al: Overepression of KIT in chromophobe renal cell carcinoma. Oncogene 22:847-852, 2003 (Pubitemid 36255820)
8. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
9. Sternberg CN, Szczylik C, Lee E, et al: A randomized, double-blind phase III study of pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 27:240s, 2009 (suppl; abstract 5021)
10. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
11. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
12. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007 (Pubitemid 46849157)
13. Gore ME, Szczylik C, Porta C, et al: Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial. Lancet Oncol 10:757-763, 2009
14. Stadler WM, Figlin RA, Ernstoff MS, et al: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). J Clin Oncol 25:243s, 2007 (suppl; abstract 5036)
15. Choueiri TK, Plantade A, Elson P, et al: Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26:127-131, 2008
16. Stein WD, Yang J, Bates SE, et al: Bevacizumab reduces the growth rate constants of renal carcinomas: A novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. The Oncologist 13:1055-1062, 2008
17. Wilkerson J, Stein WD, Kim ST, et al: Validation of a kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa: Analysis of the pivotal randomised trial. J Clin Oncol 28:366s, 2010 (suppl; abstract 4597)